Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD. Bamias G, Menghini P, Pizarro TT, Cominelli F, et al. Gut 2025;74:652-668.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bamias G, Menghini P, Pizarro TT, Cominelli F, et al. Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD. Gut 2025;74:652-668.
PMID: 39266053